2023
Patient Travel Distance to Neurologist Visits
Lin C, Hill C, Kerber K, Burke J, Skolarus L, Esper G, de Havenon A, De Lott L, Callaghan B. Patient Travel Distance to Neurologist Visits. Neurology 2023, 101: e1807-e1820. PMID: 37704403, PMCID: PMC10634641, DOI: 10.1212/wnl.0000000000207810.Peer-Reviewed Original ResearchConceptsAmyotrophic lateral sclerosisPatient travel distanceNeurologist visitNeurologic conditionsCancer careMedicare beneficiariesPrimary care physician visitsCoordinated multidisciplinary careMedian driving distanceClustering of patientsHospital referral regionsCross-sectional analysisLocal neurologistsNeurologist carePhysician visitsClinical outcomesMultidisciplinary careMedicare sampleReferral regionsLateral sclerosisNeurologic carePatientsTravel burdenNeurologistsVisits
2021
Five-Year Trends in Payments for Neurologist-Prescribed Drugs in Medicare Part D.
de Havenon A, Delic A, Dehoney S, Whetman P, Sheibani N, Callaghan B, Ney J, Esper GJ, Magliocco B, Nair KV. Five-Year Trends in Payments for Neurologist-Prescribed Drugs in Medicare Part D. Neurology 2021, 96: e2132-e2137. PMID: 33692164, PMCID: PMC8166447, DOI: 10.1212/wnl.0000000000011712.Peer-Reviewed Original Research
2019
Is There Equipoise Regarding the Optimal Medical Treatment of Patients with Asymptomatic White Matter Hyperintensities?
de Havenon A, Prabhakaran S, Turan T, Gottesman R, Yeatts S, Rost N. Is There Equipoise Regarding the Optimal Medical Treatment of Patients with Asymptomatic White Matter Hyperintensities? Journal Of Stroke And Cerebrovascular Diseases 2019, 28: 104371. PMID: 31495669, PMCID: PMC8015436, DOI: 10.1016/j.jstrokecerebrovasdis.2019.104371.Peer-Reviewed Original ResearchMeSH KeywordsAntihypertensive AgentsAsymptomatic DiseasesAttitude of Health PersonnelDisease ProgressionHealth Care SurveysHealth Knowledge, Attitudes, PracticeHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLeukoencephalopathiesNeurologistsPlatelet Aggregation InhibitorsPractice Patterns, Physicians'Therapeutic EquipoiseTreatment OutcomeConceptsAsymptomatic white matter hyperintensitiesWhite matter hyperintensitiesOptimal medical treatmentMatter hyperintensitiesMedical treatmentCognitive impairmentIntensive Blood Pressure ReductionNeurologists' attitudesBlood pressure targetsStroke prevention therapyBlood pressure reductionOptimal medical managementRegional coordinating centersMild cognitive impairmentStatin therapyIschemic strokeMicrovascular diseasePressure targetsPrevention therapyClinical outcomesFunctional disabilityMedical managementPatient populationCommon manifestationWMH progression